You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 166 No. 3, February 13, 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Metabolic Diseases
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Screening for Hemochromatosis

Arch Intern Med. 2006;166:269-270.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hereditary hemochromatosis (HH) is a common inherited disorder of iron metabolism occurring in approximately 1 in 200 to 250 individuals of northern European descent.1 This makes HH the most common inherited disorder seen in whites. Most cases of HH are caused by a single mutation in the HFE gene. This results in an increase in iron absorption from the duodenum with increased deposition of iron in the liver, heart, joints, pancreas, and other endocrine organs. Undiagnosed and untreated, progressive iron deposition can cause hepatocellular injury, activation of hepatic stellate cells, and an increase in production of collagen and other components of the extracellular matrix, leading to the development of advanced fibrosis and cirrhosis. The most common causes of death in patients with untreated HH are complications of chronic liver disease and hepatocellular cancer.2

Screening for HH either by phenotypic tests (transferrin saturation or ferritin) or by genetic testing (HFE . . . [Full Text of this Article]


AUTHOR INFORMATION
Bruce R. Bacon, MD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Screening for Hemochromatosis in Asymptomatic Subjects With or Without a Family History
Lawrie W. Powell, Jeannette L. Dixon, Grant A. Ramm, David M. Purdie, Douglas J. Lincoln, Gregory J. Anderson, V. Nathan Subramaniam, David G. Hewett, Jeffrey W. Searle, Linda M. Fletcher, Darrell H. Crawford, Helen Rodgers, Katrina J. Allen, Juleen A. Cavanaugh, and Mark L. Bassett
Arch Intern Med. 2006;166(3):294-301.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.